Royalty Pharma plc (RPRX) shareholders
Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Legorreta G. Pablo Joint filing with Legorreta Investments, LLC (7.76%) | 101,785,843 | 18.73% | 13D (active) amendment | Aug 13, 2026 |
| Morgan Stanley Joint filing with Morgan Stanley Investment Management Inc. (8.50%) | 38,907,011 | 9.20% | 13G (passive) amendment | Jun 30, 2025 |
| Capital International Investors | 37,772,419 | 8.80% | 13G (passive) amendment | Mar 31, 2026 |
| R & H Trust Co. (Guernsey) Limited Joint filing with Severgnini Achille G. (6.90%) | 29,926,170 | 6.90% | 13D (active) amendment | Apr 30, 2025 |
| BlackRock, Inc. | 25,445,414 | 5.70% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RPRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 42,931,597 | 7.47% | $2.41B | −640,036 | 0.13% |
| Capital International Investors | 35,273,770 | 6.13% | $1.98B | +268,034 | 0.41% |
| BlackRock, Inc. | 27,832,977 | 4.84% | $1.56B | +1,925,232 | 0.02% |
| FMR LLC | 24,513,814 | 4.26% | $1.37B | −638,428 | 0.06% |
| State Street Corp | 12,338,229 | 2.15% | $691.80M | +1,348,378 | 0.02% |
| Price T Rowe Associates Inc /Md/ | 11,193,657 | 1.95% | $627.63M | +9,259,396 | 0.06% |
| Swedbank AB | 10,726,608 | 1.87% | $601.44M | −860,085 | 0.52% |
| Baillie Gifford & Co | 10,015,578 | 1.74% | $561.57M | −6,140,099 | 0.51% |
| Capital World Investors | 9,517,337 | 1.66% | $533.64M | +1,480,623 | 0.06% |
| Geode Capital Management, LLC | 8,058,048 | 1.40% | $450.58M | +188,416 | 0.02% |
| Caledonia (Private) Investments Pty Ltd | 5,775,851 | 1.00% | $323.85M | −1,392,548 | 11.06% |
| Norges Bank | 5,336,084 | 0.93% | $299.19M | New | 0.03% |
| Vanguard Capital Management LLC | 4,826,617 | 0.84% | $270.63M | +294,731 | 0.01% |
| Northern Trust Corp | 4,718,859 | 0.82% | $264.59M | +910,124 | 0.03% |
| Royal London Asset Management Ltd | 4,319,595 | 0.75% | $242.20M | +511,242 | 0.45% |
| Aqr Capital Management LLC | 4,305,412 | 0.75% | $241.40M | +523,374 | 0.08% |
| Invesco Ltd. | 4,232,577 | 0.74% | $237.32M | +480,178 | 0.02% |
| Bank Of America Corp /De/ | 4,149,422 | 0.72% | $232.66M | +653,576 | 0.01% |
| Legal & General Group Plc | 3,800,504 | 0.66% | $213.09M | +437,632 | 0.04% |
| Amundi | 3,723,864 | 0.65% | $208.80M | +635,091 | 0.05% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 643 | 367M | 63.8% | 106 / 291 | 177 / 43 | 45M | 33M |
| Q1 2026 | 591 | 355M | 61.7% | 117 / 225 | 181 / 59 | 52M | 43M |
| Q4 2025 | 539 | 358M | 62.2% | 108 / 235 | 136 / 51 | 46M | 19M |
| Q3 2025 | 488 | 331M | 57.5% | 92 / 206 | 132 / 52 | 47M | 59M |
| Q2 2025 | 455 | 343M | 59.7% | 77 / 172 | 156 / 64 | 66M | 34M |
| Q1 2025 | 446 | 311M | 54.0% | 85 / 159 | 148 / 50 | 40M | 39M |
| Q4 2024 | 416 | 322M | 56.0% | 77 / 161 | 136 / 50 | 33M | 24M |
| Q3 2024 | 395 | 314M | 54.7% | 60 / 159 | 122 / 39 | 43M | 30M |
| Q2 2024 | 378 | 325M | 56.5% | 59 / 141 | 128 / 56 | 27M | 110M |
| Q1 2024 | 379 | 410M | 71.2% | 65 / 163 | 112 / 47 | 68M | 24M |
| Q4 2023 | 363 | 366M | 63.7% | 79 / 148 | 109 / 29 | 85M | 19M |
| Q3 2023 | 313 | 300M | 52.1% | 35 / 137 | 115 / 47 | 17M | 36M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
190 funds held RPRX in Q2 2026, 26% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RPRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| New Perspective Fund | 19,645,749 | 3.42% | $1.10B | 0.65% | Jun 30, 2026 |
| Capital Income Builder | 7,427,586 | 1.29% | $433.99M | 0.33% | Jul 31, 2026 |
| Growth Fund of America | 6,412,195 | 1.12% | $357.54M | 0.10% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 4,471,210 | 0.78% | $250.70M | 0.26% | Jun 30, 2026 |
| Patient Opportunity Trust | 2,500,000 | 0.43% | $140.18M | 6.98% | Jun 30, 2026 |
| VictoryShares Free Cash Flow ETF | 2,438,172 | 0.42% | $136.71M | 1.76% | Jun 30, 2026 |
| Invesco Discovery Mid Cap Growth Fund | 1,707,479 | 0.30% | $99.77M | 1.47% | Jul 31, 2026 |
| Vanguard High Dividend Yield Index Fund | 1,665,008 | 0.29% | $97.29M | 0.10% | Jul 31, 2026 |
| Growth Fund | 1,658,815 | 0.29% | $93.01M | 0.16% | Jun 30, 2026 |
| iShares Russell 1000 Value ETF | 925,878 | 0.16% | $51.91M | 0.07% | Jun 30, 2026 |
| Vanguard Global Equity Fund | 924,999 | 0.16% | $51.86M | 0.68% | Jun 30, 2026 |
| iShares U.S. Pharmaceuticals ETF | 880,087 | 0.15% | $49.35M | 4.33% | Jun 30, 2026 |
| Eventide Dividend Opportunities Fund | 774,108 | 0.13% | $43.40M | 3.05% | Jun 30, 2026 |
| iShares MSCI USA Momentum Factor ETF | 653,937 | 0.11% | $38.21M | 0.15% | Jul 31, 2026 |
| ALPS | OShares U.S. Small-Cap Quality Dividend ETF | 482,094 | 0.08% | $26.88M | 3.07% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pablo G. Legorreta | CEO, Chairman of the Board, Director | 28,011,146 | 4.87% | Nov 6, 2026 |
| Marshall Urist | EVP, Research & Investments | 1,530,889 | 0.27% | Nov 6, 2026 |
| Christopher Hite | EVP & Chairman, Partnering | 1,539,512 | 0.27% | Nov 6, 2026 |
| Terrance P. Coyne | EVP & CFO | 2,096,289 | 0.36% | Nov 6, 2026 |
| Arthur Richard McGivern | EVP, Investments & GC | – | – | Jan 6, 2026 |
| George W. Lloyd | EVP, Investments & CLO | 2,724,616 | 0.47% | Dec 19, 2025 |
| Bonnie L. Bassler | Director | 79,823 | 0.01% | Sep 30, 2026 |
| David C. Hodgson | Director | 37,873 | 0.01% | Jun 8, 2026 |
| Elizabeth H. Weatherman | Director | 13,103 | 0.00% | Jun 8, 2026 |
| Vlad Coric | Director | 15,343 | 0.00% | Jun 8, 2026 |
| Ted W. Love | Director | 58,393 | 0.01% | Jun 8, 2026 |
| Gregory Norden | Director | 196,348 | 0.03% | Jun 8, 2026 |
| Carole Ho | Director | 13,103 | 0.00% | Jun 8, 2026 |
| Catherine M. Engelbert | Director | 55,673 | 0.01% | Jun 8, 2026 |
| Henry A. Fernandez | Director | 123,524 | 0.02% | Jun 30, 2025 |
| Errol B. Desouza | Director | 81,352 | 0.01% | May 14, 2025 |
| Pharma plc Royalty | Director | – | – | Apr 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marshall Urist EVP, Research & Investments | Nov 6, 2026 | Conversion | +150,000 | – | – | 150,000 |
| Terrance P. Coyne EVP & CFO | Nov 6, 2026 | Conversion | +100,000 | – | – | 100,000 |
| Terrance P. Coyne EVP & CFO | Nov 6, 2026 | Conversion | +150,000 | – | – | 150,000 |
| Marshall Urist EVP, Research & Investments | Nov 4, 2026 | Award | +5,341 | – | – | 5,341 |
| Terrance P. Coyne EVP & CFO | Nov 4, 2026 | Award | +7,122 | – | – | 7,122 |
| Christopher Hite EVP & Chairman, Partnering | Nov 4, 2026 | Award | +7,122 | – | – | 277,523 |
| Pablo G. Legorreta CEO, Chairman of the Board, Director | Nov 4, 2026 | Award | +42,209 | – | – | 1,350,029 |
| Marshall Urist EVP, Research & Investments | Oct 5, 2026 | Sale(10b5-1 plan) | −4,126 | $57.10 | $235.59K | 0 |
| Bonnie L. Bassler Director | Sep 30, 2026 | Award | +642 | $58.41 | $37.50K | 79,823 |
| Marshall Urist EVP, Research & Investments | Sep 28, 2026 | Sale(10b5-1 plan) | −4,126 | $57.88 | $238.81K | 4,126 |
| Christopher Hite EVP & Chairman, Partnering | Sep 22, 2026 | Sale(10b5-1 plan) | −3,927 | $58.93 | $231.42K | 270,401 |
| Christopher Hite EVP & Chairman, Partnering | Sep 22, 2026 | Sale(10b5-1 plan) | −96,073 | $58.51 | $5.62M | 274,328 |
| Christopher Hite EVP & Chairman, Partnering | Aug 19, 2026 | Gift | −16,800 | – | – | 23,200 |
| Christopher Hite EVP & Chairman, Partnering | Aug 18, 2026 | Sale(10b5-1 plan) | −100,000 | $59.97 | $6.00M | 370,401 |
| Terrance P. Coyne EVP & CFO | Aug 13, 2026 | Sale(10b5-1 plan) | −1,772 | $59.14 | $104.80K | 0 |
| Terrance P. Coyne EVP & CFO | Aug 13, 2026 | Sale(10b5-1 plan) | −9,230 | $58.59 | $540.79K | 1,772 |
| Christopher Hite EVP & Chairman, Partnering | Aug 5, 2026 | Award | +11,002 | – | – | 470,401 |
| Pablo G. Legorreta CEO, Chairman of the Board, Director | Aug 5, 2026 | Award | +65,216 | – | – | 1,307,820 |
| Marshall Urist EVP, Research & Investments | Aug 5, 2026 | Award | +8,252 | – | – | 8,252 |
| Terrance P. Coyne EVP & CFO | Aug 5, 2026 | Award | +11,002 | – | – | 11,002 |
| Marshall Urist EVP, Research & Investments | Jul 1, 2026 | Sale(10b5-1 plan) | −9,099 | $55.88 | $508.45K | 0 |
| Christopher Hite EVP & Chairman, Partnering | Jun 30, 2026 | Sale(10b5-1 plan) | −29,400 | $56.44 | $1.66M | 40,600 |
| Christopher Hite EVP & Chairman, Partnering | Jun 30, 2026 | Sale(10b5-1 plan) | −600 | $57.09 | $34.25K | 40,000 |
| Christopher Hite EVP & Chairman, Partnering | Jun 30, 2026 | Sale(10b5-1 plan) | −97,446 | $56.50 | $5.51M | 461,953 |
| Christopher Hite EVP & Chairman, Partnering | Jun 30, 2026 | Sale(10b5-1 plan) | −2,554 | $57.10 | $145.83K | 459,399 |
| Bonnie L. Bassler Director | Jun 30, 2026 | Award | +689 | $54.40 | $37.48K | 79,181 |
| Marshall Urist EVP, Research & Investments | Jun 24, 2026 | Sale(10b5-1 plan) | −9,098 | $55.18 | $502.03K | 9,099 |
| Christopher Hite EVP & Chairman, Partnering | Jun 23, 2026 | Sale(10b5-1 plan) | −32,408 | $54.11 | $1.75M | 676,991 |
| Christopher Hite EVP & Chairman, Partnering | Jun 23, 2026 | Sale(10b5-1 plan) | −117,592 | $54.47 | $6.41M | 559,399 |
| Bonnie L. Bassler Director | Jun 5, 2026 | Award | +4,545 | – | – | 78,492 |
| Gregory Norden Director | Jun 5, 2026 | Award | +4,545 | – | – | 196,348 |
| Carole Ho Director | Jun 5, 2026 | Award | +4,545 | – | – | 4,545 |
| Ted W. Love Director | Jun 5, 2026 | Award | +4,545 | – | – | 58,393 |
| David C. Hodgson Director | Jun 5, 2026 | Award | +4,545 | – | – | 37,873 |
| Catherine M. Engelbert Director | Jun 5, 2026 | Award | +4,545 | – | – | 55,673 |
| Vlad Coric Director | Jun 5, 2026 | Award | +4,545 | – | – | 15,343 |
| Elizabeth H. Weatherman Director | Jun 5, 2026 | Award | +4,545 | – | – | 13,103 |
| Terrance P. Coyne EVP & CFO | May 26, 2026 | Sale(10b5-1 plan) | −64,399 | $53.98 | $3.48M | 0 |
| Marshall Urist EVP, Research & Investments | May 20, 2026 | Sale(10b5-1 plan) | −13,684 | $52.75 | $721.83K | 18,197 |
| Gregory Norden Director | May 14, 2026 | Sale(10b5-1 plan) | −3,045 | $53.00 | $161.39K | 191,803 |
| Marshall Urist EVP, Research & Investments | May 14, 2026 | Sale(10b5-1 plan) | −13,684 | $53.06 | $726.07K | 31,881 |
| Marshall Urist EVP, Research & Investments | May 6, 2026 | Award | +18,197 | – | – | 45,565 |
| Terrance P. Coyne EVP & CFO | May 6, 2026 | Award | +24,263 | – | – | 64,399 |
| Christopher Hite EVP & Vice Chairman | May 6, 2026 | Award | +24,263 | – | – | 709,399 |
| Pablo G. Legorreta CEO, Chairman of the Board, Director | May 6, 2026 | Award | +143,821 | – | – | 1,242,604 |
| Terrance P. Coyne EVP & CFO | Apr 28, 2026 | Sale(10b5-1 plan) | −32,916 | $49.78 | $1.64M | 0 |
| Terrance P. Coyne EVP & CFO | Apr 28, 2026 | Sale(10b5-1 plan) | −1,875 | $49.78 | $93.34K | 40,136 |
| Terrance P. Coyne EVP & CFO | Apr 1, 2026 | Sale(10b5-1 plan) | −1,875 | $48.33 | $90.62K | 42,011 |
| Terrance P. Coyne EVP & CFO | Apr 1, 2026 | Sale(10b5-1 plan) | −32,916 | $48.33 | $1.59M | 32,916 |
| Bonnie L. Bassler Director | Mar 31, 2026 | Award | +815 | $45.98 | $37.47K | 73,947 |
| Terrance P. Coyne EVP & CFO | Mar 23, 2026 | Sale(10b5-1 plan) | −1,875 | $45.53 | $85.37K | 43,886 |
| Terrance P. Coyne EVP & CFO | Mar 23, 2026 | Sale(10b5-1 plan) | −32,916 | $45.53 | $1.50M | 65,832 |
| Terrance P. Coyne EVP & CFO | Mar 2, 2026 | Sale(10b5-1 plan) | −583 | $47.01 | $27.41K | 45,761 |
| Terrance P. Coyne EVP & CFO | Mar 2, 2026 | Sale(10b5-1 plan) | −22,487 | $46.67 | $1.05M | 109,177 |
| Terrance P. Coyne EVP & CFO | Mar 2, 2026 | Sale(10b5-1 plan) | −10,429 | $47.01 | $490.27K | 98,748 |
| Terrance P. Coyne EVP & CFO | Mar 2, 2026 | Sale(10b5-1 plan) | −1,292 | $46.67 | $60.30K | 46,344 |
| Terrance P. Coyne EVP & CFO | Feb 23, 2026 | Sale(10b5-1 plan) | −1,875 | $45.32 | $84.98K | 47,636 |
| Terrance P. Coyne EVP & CFO | Feb 23, 2026 | Sale(10b5-1 plan) | −32,916 | $45.32 | $1.49M | 131,664 |
| Marshall Urist EVP, Research & Investments | Feb 11, 2026 | Award | +19,970 | – | – | 27,368 |
| Christopher Hite EVP & Vice Chairman | Feb 11, 2026 | Award | +26,626 | – | – | 685,136 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Royalty Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 65,491 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Marshall Urist Officer | Oct 5, 2026 | 4,126 | $235.59K | Oct 5, 2026 | Equity Performance Award |
| Marshall Urist Officer | Sep 28, 2026 | 4,126 | $238.81K | Sep 28, 2026 | Equity Performance Award |
| SCH Investment Partners LLC Officer | Sep 22, 2026 | 100,000 | $5.85M | Sep 22, 2026 | Acquired from issuer in private transaction |
| SCH Investment Partners LLC Officer | Aug 18, 2026 | 100,000 | $6.01M | Aug 18, 2026 | Acquired from issuer in private transaction |
| Terrance P. Coyne Officer | Aug 13, 2026 | 11,002 | $644.28K | Aug 13, 2026 | Acquired as compensation -- Performance Awards |
| Errol B. De Souza Former Affiliate | Aug 12, 2026 | 206,352 | $11.93M | Aug 12, 2026 | Conversion of LP Interests |
| Errol B. De Souza Former Affiliate | Aug 12, 2026 | 125,000 | $7.22M | Aug 12, 2026 | Conversion of LP Interests |
| Marshall Urist Officer | Jul 1, 2026 | 9,099 | $508.45K | Jul 1, 2026 | Equity Performance Award |
| SCH Investment Partners LLC Officer | Jul 1, 2026 | 100,000 | $5.71M | Jun 30, 2026 | Acquired from issuer in private transaction |
| Marshall Urist Officer | Jun 24, 2026 | 9,098 | $502.07K | Jun 24, 2026 | Equity Performance Award |
| SCH Investment Partners LLC Officer | Jun 23, 2026 | 150,000 | $8.17M | Jun 23, 2026 | Acquired from issuer in private transaction |
| Christopher Hite Officer | Jun 23, 2026 | 30,000 | $1.66M | Jun 23, 2026 | Purchase in IPO - Reserved Shares Program |
| Terrance P. Coyne Officer | May 26, 2026 | 64,399 | $3.47M | May 26, 2026 | Acquired as compensation -- Performance Awards |
| Marshall Urist Officer | May 20, 2026 | 13,684 | $721.84K | May 20, 2026 | Equity Performance Award |
| Marshall Urist Officer | May 14, 2026 | 13,684 | $726.14K | May 14, 2026 | Equity Performance Award |
See a number that looks wrong?